Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis
|
|
- Sabrina McKenzie
- 5 years ago
- Views:
Transcription
1 JNCI J Natl Cancer Inst (2017) 109(2): djw217 doi: /jnci/djw217 First published online October 30, 2016 Article Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis Yaxiong Zhang*, Yunpeng Yang*, Zhonghan Zhang*, Wenfeng Fang, Shiyang Kang, Youli Luo, Jin Sheng, Jianhua Zhan, Shaodong Hong, Yan Huang, Ningning Zhou, Hongyun Zhao, Li Zhang Affiliations of authors: Department of Medical Oncology (YZ, YY, ZZ, WF, JS, JZ, SH, YH, NZ, HZ, LZ) and Department of Anesthesiology (SK), Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, China (YZ, YY, ZZ, WF, SK, JS, JZ, SH, YH, NZ, HZ, LZ); Collaborative Innovation Center for Cancer Medicine, Guangzhou, China (YZ, YY, ZZ, WF, SK, JS, JZ, SH, YH, NZ, HZ, LZ); Department of Medical Oncology, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China (YL) *Authors contributed equally to this work. Correspondence to: Li Zhang, MD, Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong , P. R. China ( zhangli6@mail.sysu.edu.cn). Abstract Background: Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown. Methods: Data of complete responses (CRs) in the acute, delayed, and overall s and treatment-related adverse events (TRAEs) were extracted from electronic databases. Efficacy and toxicity were integrated by pairwise and network meta-analyses. Results: Thirty-six trials involving patients using triple regimens (NK-1RAþserotonin receptor antagonists [5HT3RA] þ dexamethasone) or duplex regimen (5HT3RAþdexamethasone) to control CINV were included in the analysis. Different NK- 1RA-based triple regimens shared equivalent effect on CRs. In patients with HEC, almost all triple regimens showed statistically significantly higher CRs than duplex regimen (odds ratio [OR] duplex/triple ¼ ). However, in patients with MEC, only aprepitant-based triple regimen showed better effect than duplex regimen statistically significantly in CRs (OR duplex/triple ¼ 0.52, 95% confidence interval [CI] ¼ 0.34 to 0.68). No statistically significant difference of TRAEs was found among different triple regimens. Palonosetron-based triple regimens were equivalent to first-generation 5HT3RAs-based triple regimens for CRs. Moreover, different doses of dexamethasone plus NK-1RA and 5HT3RA showed no statistically significant difference in CRs. Conclusions: Different NK-1RAs-based triple regimens shared equivalent effect on CINV control. Various triple regimens had superior antiemetic effect than duplex regimen in patients with HEC. Only aprepitant-based triple regimen showed better CINV control compared with duplex regimen in patients receiving MEC. Palonosetron and first-generation 5HT3RAs might share equivalent CINV control in the combination of NK-1RAs and dexamethasone. Lower doses of dexamethasone might be applied when used with NK-1RAs and 5HT3RAs. Chemotherapy-induced nausea and vomiting (CINV) are common adverse effects that often affect patients compliance with treatment and impact health-related quality of life (1,2). Patients receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) are major populations suffering nausea and vomiting (3). Corticosteroids, most Received: May 20, 2016; Revised: July 18, 2016; Accepted: August 26, 2016 The Author Published by Oxford University Press. All rights reserved. For Permissions, please journals.permissions@oup.com 1of11
2 Y. Zhang et al. 2of11 Figure 1. Profile summarizing the trial flow. commonly dexamethasone, were first used for the treatment of CINV in the early 1990s (4). Thereafter, the addition of serotonin receptor antagonists (5HT3RAs) showed additional improvement in acute CINV, which act via peripheral nervous pathways of gastrointestinal tracts (5). Furthermore, recent studies found that dexamethasone plus 5HT3RA and neurokinin-1 receptor antagonists (NK-1RAs) made greater advances in controlling CINV because NK-1RA could play a role in both acute and delayed CINV through blocking the actions of substance P (SP) in the vomiting center of the brain (5). As a result, combination antiemetic therapy is the standard regimen for patients receiving HEC or MEC to prevent CINV (6 8). Recent clinical practice guidelines recommend a 5HT3RA plus an NK-1RA and a corticosteroid for HEC, and a 5HT3RA plus a corticosteroid, with or without an NK-1 RA, for MEC (6 8). Because there are various NK-1RAs (aprepitant, casopitant, fosaprepitant, netupitant, and rolapitant) and 5HT3RAs (first generation: ondansetron and granisetron; second generation: palonosetron) for oncologists to choose from, according to sufficient clinical data, a large-scale analysis is needed to answer whether the efficacy and toxicity of antiemesis are different among those NK-1RA-based triple antiemetic regimens. Besides, it is still unclear whether the antiemetic efficacy in palonosetron-based triple regimens is better compared with first-generation 5HT3RAs-based triple regimens. Moreover, whether the doses of dexamethasone in combination with NK- 1RA plus 5HT3RA will impact the antiemetic effect is also unknown. Therefore, a network meta-analysis is an optimal method to compare different regimens because of its good agreement in the real-world situation (9,10). Methods Search Strategy and Selection Criteria We systematically searched the PubMed, Embase, and Cochrane Central Register of Controlled Trials databases using a combination of the terms neurokinin-1 receptor antagonist, aprepitant, casopitant, fosaprepitant, netupitant, and rolapitant to find relevant articles published up to February A manual search through reference lists of relevant reviews was additionally performed. Three authors carried out the literature retrieval independently (YZ, YY, ZZ). Eligible studies met the following criteria: 1) they were randomized control trials (RCTs) or prospective studies that evaluated NK-1RAbased triple antiemetic regimens in the prophylaxis of CINV; 2) efficacy and/or toxicity measures were available; 3) NK-1RA was used at the standard dose. Studies failing to meet these inclusion criteria were excluded. Outcomes Measures, Data Extraction,and Quality Assessment The outcomes of antiemetic efficacy were the proportions of patients with complete responses (CRs) and no clinically significant nausea in the acute (0 24 hours after chemotherapy), delayed (> hours after chemotherapy), and overall (0 120 hours) s. The toxic outcome was defined as treatment-related adverse events (TRAEs). The assessment of efficacy and toxicity occurred during the first cycle of chemotherapy. The data on trial name, therapeutic and antiemetic regimens, and clinical outcomes were extracted by two investigators independently (YZ and ZZ). HEC, such as anthracycline plus cyclophosphamide (AC) or cisplatin, and MEC, such as carboplatin or oxaliplatin, were defined according to the National Comprehensive Cancer Network Antiemesis Guideline Version 2, 2016 (11). Cochrane risk of bias was used to assess the quality of all included studies by another two reviewers (YL and YY) (12). Discrepancies were discussed by all investigators to reach a consensus. More details on this can be found in Supplementary Figure 1 (available online). Statistical Analyses First, we conducted pair-wise meta-analyses using a randomeffects model to synthesize studies comparing the same pair of antiemetic treatments. The results were reported as pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Statistical heterogeneity across studies was assessed with a forest plot and the inconsistency statistic (I 2 ). Statistical significance was set at a P value of.05. All calculations were
3 3of11 JNCI J Natl Cancer Inst, 2017, Vol. 109, No. 2 Table 1. Characteristics of included studies for network meta-analyses (data of complete response and treatment-related adverse events) Complete response Trial Emetogenic potential Chemotherapy regimens No. Regimens* Total (each day) dose (mg) of D Overall Acute Delayed TRAE 2003 Chawla High Cisplatin-based chemotherapy 131 AþDþO 52 (20, 8, 8, 8, 8) 93/ /131 95/132 58/ DþO 52 (20, 8, 8, 8, 8) 55/126 89/126 56/126 55/ de Wit High Cisplatin-based chemotherapy 80 AþDþO 52 (20, 8, 8, 8, 8) 51/80 NA NA 21/62 84 DþO 52 (20, 8, 8, 8, 8) 41/84 NA NA 15/ Hesketh High Cisplatin-based chemotherapy 260 AþDþO 36 (12, 8, 8, 8) 118/ / /260 38/ DþO 68 (20, 16, 16, 16) 104/ / /260 29/ Poli-Bigelli High Cisplatin-based chemotherapy 261 AþDþO 36 (12, 8, 8, 8) 114/ / /260 55/ DþO 68 (20, 16, 16, 16) 84/ /263 89/263 41/ Warr High AC 433 AþDþO 12 (12) 220/ / /433 94/ DþO 20 (20) 178/ / /424 84/ Schmoll High Cisplatin-based chemotherapy 243 AþDþO 36 (12, 8, 8, 8) 174/ / /243 57/ DþO 68 (20, 16, 16, 16) 146/ / /241 59/ Herrington High Cisplatin-based chemotherapy or AC 27 AþDþP 36 (12, 8, 8, 8) 14/27 19/27 16/27 NA 16 DþP 42 (18, 8, 8, 8) 4/16 8/16 4/16 NA 2009 Arpornwirat Moderate Carboplatin-based chemotherapy 602 CþDþO 8 (8) i.v. 489/ / /602 NA 121 DþO 8 (8) i.v. 84/ /121 84/121 NA 2009 Gore Mixed Mixed 28 AþDþO 20 (8, 4, 4, 4) 8/28 17/28 10/28 7/32 18 DþO 40 (16, 8, 8, 8) 1/18 7/18 1/18 1/ Grunberg High Cisplatin-based chemotherapy 535 CþDþO 36 (12, 8, 8, 8) or 60 (12, 16, 16, 16) 442/ /535 NA 59/ DþO 68 (20, 16, 16, 16) 175/ /265 NA 29/ Herrstedt High AC 1438 CþDþO 8 (8) i.v. 1053/ / /1438 NA 479 DþO 8 (8) i.v. 282/ / /479 NA 2009 Roila High Cisplatin-based chemotherapy 327 CþDþO 36 (12, 8, 8, 8) or 60 (12, 16, 16, 16) 256/ / /327 NA 82 AþDþO 36 (12, 8, 8, 8) 59/82 74/82 59/82 NA 2009 Yeo High AC 62 AþOþD 12 (12) 29/62 45/62 40/62 NA 62 OþD 20 (20) 26/62 45/62 36/62 NA 2010 Rapoport Mixed AC or non-ac 430 AþOþD 12 (12) 292/ / /430 31/ OþD 20 (20) 229/ / /418 39/ Takahashi High Cisplatin-based chemotherapy 146 AþGþD 14 (6, 4, 4) i.v. 103/ / /146 35/ GþD 28 (12, 8, 8) i.v. 75/ /150 77/149 30/ Grunberg High Cisplatin-based chemotherapy 1109 FþOþD 52 (12, 8, 16, 16) 797/ / /1109 NA 1138 AþOþD 36 (12, 8, 8, 8) 823/ / /1138 NA 2012 Hesketh Moderate Oxaliplatin-based chemotherapy 355 CþOþD 8 (8) i.v. 305/ / /355 34/ OþD 8 (8) i.v. 298/ / /352 33/ Saito High Cisplatin-based chemotherapy 173 FþGþD 22 (10, 4, 8) i.v. 111/ / /173 45/ GþD 36 (20, 8, 8) i.v. 79/ /167 81/166 48/ Tanioka Moderate Carboplatin-based chemotherapy 45 AþGþD 20 (12, 4, 4) i.v. 28/45 44/45 28/45 NA 46 GþD 36 (20, 8, 8) i.v. 24/46 44/46 24/46 NA 2014 Aapro High AC 724 NþPþD 12 (12) 538/ / /724 59/ PþD 20 (20) 483/ / /725 52/725 (continued)
4 Y. Zhang et al. 4of11 Table 1. (continued) Complete response Trial Emetogenic potential Chemotherapy regimens No. Regimens* Total (each day) dose (mg) of D Overall Acute Delayed TRAE 2014 Gralla Mixed Mixed 309 NþPþD 36 (12, 8, 8, 8) or 12 (12) 103 AþPþD 36 (12, 8, 8, 8) or 12 (12) 250/309 NA NA 16/308 78/103 NA NA 3/ Hesketh High Cisplatin-based chemotherapy 135 NþPþD 36 (12, 8, 8, 8) 121/ / /135 21/ AþOþD 36 (12, 8, 8, 8) 116/ / /134 26/ Hu High Cisplatin-based chemotherapy 204 AþGþD (6, 3.75, 3.75, 3.75) 142/ / /204 24/ GþD 33 (10.5, 7.5, 7.5, 7.5) 119/ / /207 28/ Ito Moderate Carboplatin-based chemotherapy 66 A þ 5-HT3RAþD 36 (20, 8, 8) 53/66 NA NA NA 67 5-HT3RAþD 36 (20, 8, 8) 45/67 NA NA NA 2014 Schmitt Moderate High-dose melphalan 181 AþGþD 8 (4, 2, 2) 105/ / /181 NA 181 GþD 16 (8, 4, 4) 72/ /181 83/181 NA 2015 Kitayama Moderate Oxaliplatin-based chemotherapy or others 35 FþDþG 4.95 (4.95) i.v. 24/35 35/35 24/35 NA 35 DþP 9.9 (9.9) i.v. 26/35 33/35 26/35 NA 2015 Maehara Moderate Carboplatin-based chemotherapy 11 AþDþ5-HT3RA 16 (8, 4, 4) i.v. D1 11/11 11/11 11/11 NA 12 D þ 5-HT3RA 32 (16, 8, 8) i.v. D1 5/12 6/12 8/12 NA 2015 Nishimura Moderate Oxaliplatin-based chemotherapy 187 AþDþ5-HT3RA 14.6 (6.6, 4, 4) i.v. D1 159/ / /187 NA 183 D þ 5-HT3RA 25.9 (9.9, 8, 8) i.v. D1 136/ / /183 NA 2015 Schwartzberg Mixed AC or non-ac 666 RþGþD 20 (20) 457/ / /666 64/ GþD 20 (20) 385/ / /666 52/ Yahata Moderate Carboplatin-based chemotherapy 151 AþDþG/O 20 (20) i.v. 93/ /151 96/151 NA 146 DþG/O 20 (20) i.v. 69/ /146 72/146 NA 2015 Rapoport (HEC) High Cisplatin-based chemotherapy 90 RþDþO 68 (20, 16, 16, 16) 56/90 79/90 57/90 9/90 91 DþO 68 (20, 16, 16, 16) 42/91 61/91 44/91 8/ Rapoport (HEC1) High Cisplatin-based chemotherapy 264 RþGþD 68 (20, 16, 16, 16) 185/ / /264 2/ GþD 68 (20, 16, 16, 16) 148/ / /262 10/ Rapoport (HEC2) High Cisplatin-based chemotherapy 271 RþGþD 68 (20, 16, 16, 16) 183/ / /271 15/ GþD 68 (20, 16, 16, 16) 165/ / /273 12/ Ando High Cisplatin-based chemotherapy 48 AþDþP/G/AZ ( , , , ) 41/48 47/48 42/48 NA 45 FþDþP/G/AZ ( , , , ) 37/45 44/45 38/45 NA 2016 Micha Moderate Carboplatin-based chemotherapy 10 AþDþP NA 6/10 8/10 6/10 NA 10 FþDþP NA 6/10 7/10 6/10 NA 2016 Weinstein Moderate Non-AC 502 FþDþO NA 387/ / /502 43/ DþO NA 333/ / /498 45/497 *Regimens of neurokinin-1 receptor antagonists: A) p.o. 125 mg D1, 80 mg D2 D3/80 mg D2 D5; C) p.o. 50/100/150 mg D1 D3 or p.o. 150 mg D1þ 50 mg D2 D3 or p.o. 150 mg D1 or i.v. 90 mg D1þp.o. 50 mg D2 D3 or i.v. 90 mg D1; F) i.v. 150 mg D1; N) p.o. 300 mg D1; R) p.o. 180 mg D1. 5-HT3RA ¼ serotonin receptor antagonist; A ¼ aprepitant; AC ¼ anthracycline and cyclophosphamide; AZ ¼ azasetron; C ¼ casopitant; D ¼ dexamethasone; F ¼ fosaprepitant; G ¼ granisetron; N ¼ netupitant; NA ¼ not available; O ¼ ondansetron; P ¼ palonosetron; R ¼ rolapitant; TRAE ¼ treatment-related adverse event.
5 5of11 JNCI J Natl Cancer Inst, 2017, Vol. 109, No. 2 Table 2. Binary comparison of NK-1RA-based triple regimens vs conventional duplex regimens for antiemetic efficacy and toxicity measured as complete response and treatment-related adverse events Outcome No. of trials (No. of participants) References OR* (95% CI) in random model Effect size Heterogeneity Z P P I 2,% Overall CR (Total) 30 (15 427) (17 27,29 31,33 36,39 48,51) 1.70 (1.56 to 1.85) < Acute CR (Total) 28 (15 142) (17,19 27,29 31,33 36,39,41 48,51) 1.53 (1.36 to 1.71) 7.32 < Delayed CR (Total) 27 (14 340) (17,19 25,27,29 31,33 36,39,41 48,51) 1.68 (1.53 to 1.84) < Overall CR (HEC) 17 (9425) (17 23,26 27,29,31,34,36,39,45,46) 1.72 (1.53 to 1.93) 9.21 < Acute CR (HEC) 16 (9273) (17,19 23,26,27,29,31,34,36,39,45,46) 1.52 (1.32 to 1.75) 5.74 < Delayed CR (HEC) 15 (8471) (17,19 23,27,29,31,34,36,39,45,46) 1.73 (1.53 to 1.96) 8.54 < Overall CR (MEC) 10 (3776) (24,33,35,40 44,48,51) 1.68 (1.39 to 2.03) 5.38 < Acute CR (MEC) 9 (3643) (24,33,35,41 44,48,51) 1.54 (1.16 to 2.03) Delayed CR (MEC) 9 (3643) (24,33,35,41 44,48,51) 1.62 (1.37 to 1.93) 5.59 < TRAE 19 (11 507) (17 22,25,26,30,31,33,34,36,39,45 47,51) 1.09 (0.97 to 1.22) *Represents OR triple/duplex in cancer patients using NK-1RA-based triple regimens or conventional duplex regimens in preventing chemotherapy-induced nausea and vomiting. CI ¼ confidence interval; CR ¼ complete response; HEC ¼ highly emetogenic chemotherapy; MEC ¼ moderately emetogenic chemotherapy; OR ¼ odds ratio; TRAE ¼ treatment-related adverse event; NK-1RA ¼ neurokinin-1 receptor antagonist. Two-sided test for pooled analysis (Z test). Two-sided test for heterogeneity (I 2 ). performed using REVIEW MANAGER (version 5.2 for Windows; the Cochrane Collaboration, Oxford, UK). The statistical methods to detect funnel plot asymmetry were the rank correlation test of Begg and Mazumdar and the regression asymmetry test of Egger (13,14). Secondly, a random-effects network within a Bayesian framework using the Markov chain Monte Carlo methods was built using ADDIS 1.15 (15, 16). We networked binary clinical outcomes within studies and specified the relations among the ORs across studies to make comparisons of different antiemetic treatments in terms of efficacy and/or toxicity. P values of less than.05 and 95% confidence intervals were used to assess statistical significance. The inconsistency within this multiple treatment comparison was evaluated by a variance calculation as previously described (16). All statistical tests were two-sided. Results Eligible Studies and Population Characteristics We identified 1796 records using the search strategy and included 35 studies (17 51), including 36 trials involving cancer patients using NK-1RA-based triple antiemetic regimens (NK-1RAþ5HT3RAþdexamethasone, n ¼ ) or conventional duplex control regimen (5HT3RAþ dexamethasone, n ¼ 6838) to control for CINV in this meta-analysis. Figure 1 shows the flow chart for the study selection procedure. There were 21, 11, and four trials that used HEC (17 23,26 29,31,32,34,36,38,39,45,46,49), MEC (24,33,35,40 44,48,50,51), and mixed chemotherapy regimens (25,30,37,47), respectively. Table 1 and Supplementary Table 1 (available online) give more detailed characteristics of all the studies included in our analyses. Pair-Wise Meta-Analyses for Antiemetic Efficacy and Toxicity NK-1RAs-based triple regimens showed statistically significantly superior antiemetic effect in overall, acute, and delayed CRs compared with conventional duplex regimens in overall patients, patients with HEC, and patients with MEC (Table 2). Similar results were found when no clinically significant nausea was the toxicity investigated (Supplementary Table 2, available online). However, no statistically significant difference of TRAE was found between NK-1RA-based triple regimens and duplex control regimen (Table 2). We used funnel plots to assess the publication bias of the literature in this study. All the shapes of the funnels were close to symmetric, and no publication bias was found according to Begg s test and Egger s test (P >.05). Networks for Multiple Treatment Comparisons Network A was designed for multiple treatment comparison of different NK-1RA-based triple antiemetic regimens (NK- 1RAþ5HT3RAþdexamethasone) and the conventional duplex control regimen (5HT3RAþdexamethasone) (Figure 2A). Network B established the comparison of palonosetron-based triple regimen (NK-1RAþpalonosetronþdexamethasone) and first-generation 5HT3RAs-based triple regimen (NK-1RAþ1st generation 5HT3RAsþdexamethasone) through duplex regimens (palonosetronþdexamethasone and first-generation 5HT3RAsþdexamethasone) (Figure 2B). In addition, network C was built for multiple treatment comparison of NK-1RA-based triple antiemetic regimens and conventional duplex control regimens with various doses of dexamethasone (Figure 2C). Network Meta-Analyses for Antiemetic Efficacy and Toxicity According to the data based on network A, various NK-1RAsbased triple regimens (aprepitant, casopitant, fosaprepitant, netupitant, and rolapitant) shared equivalent antiemetic effect in overall, acute, and delayed CRs without statistically significant differences in odds ratios. In all patients and patients with HEC, almost all NK-1RAs-based triple regimens showed statistically significantly higher CRs in all s vs duplex control regimen (OR duplex/triple ¼ ), while only netupitantbased triple regimen had a statistically nonsignificant superior
6 Y. Zhang et al. 6of11 Figure 2. Network established for multiple treatment comparisons. A) For different NK-1RA-based triple antiemetic regimens (NK 1RAþ5 HT3RAþD) and conventional duplex control regimens (5 HT3RAþD). B) For NK-1RA-based triple antiemetic regimens and conventional duplex control regimens including P or other 5 HT3RAs. C) For NK-1RA-based triple antiemetic regimens and conventional duplex control regimens with various doses of D (low-dose D, <20mg; moderate-dose D, 20 39mg; high-dose D, >39 mg). 5-HT3RA ¼ serotonin receptor antagonist; A ¼ aprepitant; C ¼ casopitant; D ¼ dexamethasone; F ¼ fosaprepitant; N ¼ netupitant; NK-1RA ¼ neurokinin-1 receptor antagonist; R ¼ rolapitant; P ¼ palonosetron. antiemetic efficacy compared with duplex control regimen in terms of acute CR. However, in patients with MEC, only aprepitant-based triple regimen showed a statistically significantly better antiemetic effect than duplex control regimen in all outcome measures of efficacy (OR duplex/triple ¼ 0.52, 95% CI ¼ 0.34 to 0.68). We observed no statistically significant difference in the antiemetic effect of TRAE among different NK-1RA-based triple regimens vs the duplex control regimen (Table 3). Subgroup Analyses and Consistency Evaluation According to the data based on network B, the antiemetic efficacy of palonosetron-based triple regimens was similar to firstgeneration 5HT3RAs-based triple regimens for CRs in all s. Moreover, different doses of dexamethasone in combination with NK-1RA plus 5HT3RA showed no statistically significant difference in terms of CRs in all s (Table 4). All the network meta-analyses in our study were used in both the consistency model and the inconsistency model. The variances of those two models were roughly equal. As a result, inconsistency did not appear to be present, and we used the consistency model to show our results. Discussion To our knowledge, this is the first meta-analysis to compare the antiemesis efficacy among various NK-1RAs-based triple regimens. Our study showed that different NK-1RAs-based triple regimens had an equivalent effect on CINV control in the overall, acute, and delayed s after chemotherapy. Almost all the NK-1RAs-based triple regimens showed statistically significant higher CRs in all s compared with duplex control regimen in patients with HEC. However, only aprepitant-based triple regimen provided statistically significantly better CINV prevention vs duplex control regimen in patients receiving MEC. Our study also found that palonosetron and first-generation 5HT3RAs had similar effectiveness for CINV control in all s when used with NK-1RAs. Moreover, there was no difference between different doses of dexamethasone in the prevention of CINV in all s when combined with NK-1RAs and 5HT3RAs. Consistent with the results of individual RCTs, our study confirmed that NK1RAs-based triple regimen had higher efficacy of CINV control than duplex control regimen in patients receiving HEC. As expected, we also found that various NK-1RAsbased triple regimens showed a similar effect on CINV control in all s. Thus any NK-1RAs-based triple regimen could be used for patients receiving HEC. To date, guidelines only recommend NK1RAs-based triple regimens for patients who receive HEC or anthracycline-cyclophosphamide treatment. Our study demonstrated that patients who receive MEC could also derive clinically significant benefit from applying NK-1RAs-based triple regimens that are of a similar magnitude as patients receiving HEC. Our findings suggest the application of NK-1RAs-based triple regimens for patients receiving MEC. However, subgroup analyses indicated that only aprepitant, rather than other NK- 1RAs, was associated with statistically significantly increased CINV control compared with duplex control regimen in patients receiving MEC. Therefore, aprepitant might be the preferred choice when applying triple regimens to patients receiving MEC. Palonosetron is a second-generation 5-HT3 receptor antagonist with higher binding affinity against 5-HT3 receptor and longer half-time than first-generation 5-HT3 receptor antagonists (granisetron, dolasetron, and ondansetron) (52,53). The high affinity and long half-life of palonosetron might explain its better antiemetic effect throughout the delayed emesis risk period compared with first-generation 5-HT3 receptor antagonists. Several large randomized III studies and meta-analyses assessed the effectiveness of palonosetron compared with first-generation 5-HT3 receptor antagonists in controlling vomiting emesis induced by both HEC and MEC. These studies demonstrated that palonosetron was superior to first-generation 5-HT3 receptor antagonists in preventing CINV in both the delayed and overall
7 7of11 JNCI J Natl Cancer Inst, 2017, Vol. 109, No. 2 Table 3. Odds ratios and 95% confidence intervals for antiemetic efficacy and toxicity measured as complete response and treatment-related adverse events according to multiple treatment comparisons based on network A* Overall CR (total), No. of trials ¼ 36 (17 51) (n ¼ 6838) 0.58 (0.51 to 0.65) A þ 5 HT3RAþD (n ¼ 4461) 0.53 (0.44 to 0.64) 0.91 (0.73 to 1.14) C þ 5 HT3RAþD (n ¼ 3257) 0.61 (0.48 to 0.74) 1.04 (0.84 to 1.28) 1.15 (0.84 to 1.51) F þ 5 HT3RAþD (n ¼ 1874) 0.60 (0.44 to 0.77) 1.02 (0.77 to 1.33) 1.14 (0.78 to 1.55) 0.99 (0.69 to 1.36) N þ 5 HT3RAþD (n ¼ 1168) 0.62 (0.50 to 0.76) 1.07 (0.85 to 1.35) 1.18 (0.88 to 1.56) 1.03 (0.77 to 1.38) 1.04 (0.77 to 1.49) R þ 5 HT3RAþD (n ¼ 1291) Acute CR (total), No. of trials ¼ 33 (17,19 36,38,39,41 51) (n ¼ 6687) 0.64 (0.53 to 0.76) A þ 5 HT3RAþD (n ¼ 4212) 0.67 (0.48 to 0.91) 1.05 (0.73 to 1.50) C þ 5 HT3RAþD (n ¼ 3257) 0.55 (0.38 to 0.77) 0.86 (0.59 to 1.20) 0.82 (0.51 to 1.30) F þ 5 HT3RAþD (n ¼ 1874) 0.64 (0.36 to 1.02) 1.00 (0.57 to 1.64) 0.95 (0.52 to 1.71) 1.16 (0.61 to 2.10) N þ 5 HT3RAþD (n ¼ 859) 0.64 (0.46 to 0.86) 0.99 (0.69 to 1.40) 0.95 (0.61 to 1.44) 1.16 (0.73 to 1.84) 1.00 (0.56 to 1.82) R þ 5 HT3RAþD (n ¼ 1291) Delayed CR (total), No. of trials ¼ 32 (17,19 25,27 36,38,39,41 51) (n ¼ 6422) 0.57 (0.50 to 0.65) A þ 5 HT3RAþD (n ¼ 4212) 0.57 (0.45 to 0.74) 1.00 (0.78 to 1.33) C þ 5 HT3RAþD (n ¼ 2722) 0.64 (0.50 to 0.80) 1.11 (0.89 to 1.43) 1.12 (0.80 to 1.55) F þ 5 HT3RAþD (n ¼ 1874) 0.65 (0.45 to 0.90) 1.13 (0.78 to 1.61) 1.13 (0.73 to 1.71) 1.02 (0.66 to 1.52) N þ 5 HT3RAþD (n ¼ 859) 0.61 (0.49 to 0.77) 1.07 (0.83 to 1.39) 1.08 (0.76 to 1.49) 0.96 (0.70 to 1.33) 0.95 (0.64 to 1.45) R þ 5 HT3RAþD (n ¼ 1291) Overall CR (HEC), No. of trials ¼ 21 (17 23,26 29,31,32,34,36,38,39,45,46,49) (n ¼ 4095) 0.60 (0.51 to 0.70) A þ 5 HT3RAþD (n ¼ 3249) 0.47 (0.36 to 0.60) 0.77 (0.60 to 1.04) C þ 5 HT3RAþD (n ¼ 2300) 0.58 (0.44 to 0.78) 0.97 (0.75 to 1.30) 1.24 (0.86 to 1.84) F þ 5 HT3RAþD (n ¼ 1327) 0.66 (0.45 to 0.88) 1.10 (0.75 to 1.51) 1.39 (0.89 to 2.07) 1.12 (0.70 to 1.67) N þ 5 HT3RAþD (n ¼ 859) 0.62 (0.46 to 0.81) 1.04 (0.74 to 1.43) 1.32 (0.88 to 1.93) 1.06 (0.69 to 1.58) 0.93 (0.62 to 1.50) R þ 5 HT3RAþD (n ¼ 625) Acute CR (HEC), No. of trials ¼ 20 (17,19 23,26 29,31,32,34,36,38,39,45,46,49) (n ¼ 4011) 0.71 (0.56 to 0.88) A þ 5 HT3RAþD (n ¼ 3169) 0.65 (0.41 to 0.93) 0.91 (0.55 to 1.37) C þ 5 HT3RAþD (n ¼ 2300) 0.53 (0.30 to 0.84) 0.75 (0.43 to 1.13) 0.82 (0.43 to 1.51) F þ 5 HT3RAþD (n ¼ 1327) 0.64 (0.34 to 1.03) 0.91 (0.46 to 1.52) 1.00 (0.48 to 1.91) 1.21 (0.57 to 2.50) N þ 5 HT3RAþD (n ¼ 859) 0.55 (0.35 to 0.82) 0.78 (0.47 to 1.22) 0.86 (0.48 to 1.56) 1.04 (0.57 to 2.03) 0.86 (0.46 to 1.81) R þ 5 HT3RAþD (n ¼ 625) (continued)
8 Y. Zhang et al. 8of11 Delayed CR (HEC), No. of trials ¼ 19 (17,19 23,27 29,31,32,34,36,38,39,45,46,49) (n ¼ 3746) 0.57 (0.46 to 0.68) A þ 5 HT3RAþD (n ¼ 3169) 0.50 (0.32 to 0.72) 0.86 (0.56 to 1.29) C þ 5 HT3RAþD (n ¼ 1765) 0.64 (0.43 to 0.91) 1.11 (0.76 to 1.59) 1.29 (0.76 to 2.19) F þ 5 HT3RAþD (n ¼ 1327) 0.65 (0.41 to 0.95) 1.15 (0.71 to 1.73) 1.33 (0.73 to 2.31) 1.03 (0.58 to 1.75) N þ 5 HT3RAþD (n ¼ 859) 0.59 (0.42 to 0.83) 1.02 (0.71 to 1.56) 1.18 (0.72 to 2.09) 0.92 (0.57 to 1.57) 0.90 (0.55 to 1.64) R þ 5 HT3RAþD (n ¼ 625) Overall CR (MEC), No. of trials ¼ 11 (24,33,35,40 44,48,50,51) (n ¼ 1641) 0.52 (0.34 to 0.68) A þ 5 HT3RAþD (n ¼ 651) 0.65 (0.42 to 1.13) 1.25 (0.78 to 2.59) C þ 5 HT3RAþD (n ¼ 957) 0.66 (0.42 to 1.19) 1.28 (0.78 to 2.73) 1.02 (0.50 to 2.07) F þ 5 HT3RAþD (n ¼ 547) Acute CR (MEC), No. of trials ¼ 10 (24,33,35,41 44,48,50,51) (n ¼ 1574) 0.39 (0.14 to 0.77) A þ 5 HT3RAþD (n ¼ 585) 0.83 (0.24 to 2.55) 2.05 (0.58 to 9.76) C þ 5 HT3RAþD (n ¼ 957) 0.63 (0.14 to 1.62) 1.61 (0.38 to 5.47) 0.78 (0.11 to 3.14) F þ 5 HT3RAþD (n ¼ 547) Delayed CR (MEC), No. of trials ¼ 10 (24,33,35,41 44,48,50,51) (n ¼ 1574) 0.54 (0.35 to 0.80) A þ 5 HT3RAþD (n ¼ 585) 0.71 (0.40 to 1.24) 1.30 (0.66 to 2.68) C þ 5 HT3RAþD (n ¼ 957) 0.65 (0.39 to 1.28) 1.20 (0.67 to 2.70) 0.92 (0.45 to 2.31) F þ 5 HT3RAþD (n ¼ 547) Treatment related adverse event, No. of trials ¼ 21 (17 22,25,26,30,31,33,34,36 39,45 47,51) (n ¼ 5490) 0.89 (0.74 to 1.06) A þ 5 HT3RAþD (n ¼ 2453) 0.95 (0.63 to 1.41) 1.06 (0.69 to 1.64) C þ 5 HT3RAþD (n ¼ 890) 1.12 (0.75 to 1.61) 1.26 (0.82 to 1.89) 1.20 (0.68 to 2.00) F þ 5 HT3RAþD (n ¼ 675) 0.89 (0.60 to 1.29) 1.01 (0.66 to 1.45) 0.95 (0.54 to 1.62) 0.79 (0.46 to 1.36) N þ 5 HT3RAþD (n ¼ 1168) 0.91 (0.64 to 1.31) 1.02 (0.69 to 1.60) 0.96 (0.59 to 1.69) 0.81 (0.49 to 1.39) 1.01 (0.61 to 1.76) R þ 5 HT3RAþD (n ¼ 1291) *5 HT3RA ¼ serotonin receptor antagonist; A ¼ aprepitant; C ¼ casopitant; CR ¼ complete response; D ¼ dexamethasone; F ¼ fosaprepitant; HEC ¼ highly emetogenic chemotherapy; MEC ¼ moderately emetogenic chemotherapy; N ¼ netupitant; R ¼ rolapitant. (54 57). However, in these studies, palonosetron or first-generation 5-HT3 receptor antagonists were used without the presence of NK-1RAs. Thus it is still unclear if palonosetron would be more effective than first-generation 5-HT3 receptor antagonists in CINV control when NK-1RAs were used. Our study found that palonosetron and first-generation 5HT3RAs showed an equivalent effect on CINV control in all s in the presence of NK-1RAs. Therefore, because of its higher cost, palonosetron may not be recommended as the preferred 5-HT3 receptor antagonist. Further clinical trials comparing the effectiveness of palonosetron and first-generation 5HT3RAs when combined with NK-1RAs are warranted to verify our findings. Because of a lack of other effective antiemetics, high doses of dexamethasone were used to improve CINV control.
9 9of11 JNCI J Natl Cancer Inst, 2017, Vol. 109, No. 2 Table 4. Odds ratios and confidence intervals for antiemetic efficacy measured as complete response according to multiple treatment comparison based on network B and network C* Overall CR (total), No. of trials ¼ 28 (17 27,29 31,33 36,38,39,41,42,45 48,51) NK-1RA-based triple regimen (palonosetron) (n ¼ 886) 1.65 (0.85 to 3.09) NK-1RA -based triple regimen (nonpalonosetron ) (n ¼ 7720) Acute CR (total), No. of trials ¼ 27 (17,19 27,29 31,33 36,38,39,41,42,45 48,51) NK-1RA-based triple regimen (palonosetron) (n ¼ 886) 2.12 (0.59 to 10.09) NK-1RA-based triple regimen (nonpalonosetron ) (n ¼ 7640) Delayed CR (total), No. of trials ¼ 26 (17,19 25,27,29 31,33 36,38,39,41,42,45 48,51) NK-1RA-based triple regimen (palonosetron) (n ¼ 886) 1.55 (0.71 to 2.74) NK-1RA-based triple regimen (nonpalonosetron ) (n ¼ 7105) Overall CR (total), No. of trials ¼ 29 (17 25,27,29 36,39 48) NK-1RA-based triple regimen (high-dose D) (n ¼ 1945) 1.06 (0.84 to 1.36) NK-1RA-based triple regimen (moderate-dose D) (n ¼ 3050) 1.13 (0.78 to 1.65) 1.06 (0.80 to 1.41) NK-1RA-based triple regimen (low-dose D) (n ¼ 4808) Acute CR (total), No. of trials ¼ 27 (17,19 25,27,29 36,39,41 48) NK-1RA-based triple regimen (high-dose D) (n ¼ 1865) 1.16 (0.82 to 1.66) NK-1RA-based triple regimen (moderate-dose D) (n ¼ 2984) 1.34 (0.78 to 2.48) 1.15 (0.76 to 1.89) NK-1RA-based triple regimen (low-dose D) (n ¼ 4808) Delayed CR (total), No. of trials ¼ 27 (17,19 25,27,29 36,39,41 48) NK-1RA-based triple regimen (high-dose D) (n ¼ 1865) 0.96 (0.73 to 1.30) NK-1RA-based triple regimen (moderate-dose D) (n ¼ 2984) 1.03 (0.67 to 1.61) 1.07 (0.76 to 1.49) NK-1RA-based triple regimen (low-dose D) (n ¼ 4808) *Dexamethasone: low-dose D, <20mg; moderate-dose D, 20 39mg; high-dose D, >39 mg. CR ¼ complete response; D ¼ dexamethasone; NK-1RA ¼ neurokinin-1 receptor antagonist. According to a meta-analysis of 32 studies published from 1966 to 1999, the mean total dose of dexamethasone was 56 mg (58). A high dose of dexamethasone was associated with several side effects, such as hypertension, hyperglycemia, and insomnia. However, there was no strong evidence to support the relationship between the higher dose of dexamethasone and better efficacy in CINV control (59,60). In addition, several NK-1RAs such as aprepitant, fosaprepitant, and netupitant were CYP3A4 inhibitors. Thus the dose of dexamethasone should be decreased when used with these NK-1RAs because of CYP3A4 inhibition. Moreover, data from clinical trials suggested that in combination with NK-1RAs and 5HT3RAs, low dose of dexamethasone also showed clear efficacy (31,36,39). Therefore, the optimal dose of dexamethasone in NK-1RAs-based triple regimens remains unknown. According to our study, there was no difference between different doses of dexamethasone in the prevention of CINV in all s when combined with NK-1RAs and 5HT3RAs. To minimize the adverse events related to dexamethasone, a lower dose of dexamethasone might be used with NK-1RAs and 5HT3RAs. However, dose-finding studies for dexamethasone should be conducted in combination with NK-1RAs and 5HT3RAs to confirm these findings. Olanzapine is an atypical antipsychotic drug that blocks multiple neuronal receptors involved in the nausea and vomiting pathways (61). It has been studied for CINV control, especially in patients presenting with nausea and vomiting refractory to standard antiemetics (61). A previous study showed that olanzapine had similar antiemetic effect compared with aprepitant in patients with HEC in combination with dexamethasone and 5HT3RAs (62). Recently, a single-arm trial reported that preventive use of olanzapine combined with triplet therapy (NK-1RA, 5HT3RA, and dexamethasone) showed better antiemetic effect than those from previously reported studies of triplet therapy (63). However, our study did not cover the evidence of olanzapine in CINV control because of limited data, which was not enough for multiple treatment comparisons. Future analyses are warranted to compare olanzapine-based regimens with NK-1RAs-based regimens in CINV control. According to our results, we found that the odds ratios for both the delayed and overall appeared to be very similar in most end points. It seemed that the overall results didn t add substantially to the current knowledge. Acute and delayed results might represent all of the useful information from this analysis. Further research about whether
10 Y. Zhang et al. 10of11 the overall result should be excluded in future study design, statistical analysis, and regulatory review is needed. Our study is not without limitations. First, the lack of connections in the networks made the results dependent on only a few studies so that some of the presented estimates were based exclusively on indirect evidence. Second, we were not able to extract specific patients data on HEC or MEC in some of the included studies that enrolled mixed patients. Third, we could not compare netupitant-based triple regimen and rolapitant-based triple regimen with other NK-1RAs-based triple regimens. Future studies were warranted to confirm our results. Despite the above limitations, our study confirmed that different NK-1RAs-based triple regimens were associated with an equivalent effect on CINV control in all the s. Various NK- 1RAs-based triple regimens had superior antiemetic effect than duplex control regimen in patients with HEC. Only aprepitantbased triple regimen showed better CINV control compared with duplex control regimen in patients receiving MEC. Moreover, palonosetron and first-generation 5HT3RAs might share equivalent effect on CINV control in the combination of NK-1RAs and dexamethasone. A lower dose of dexamethasone might be applied when used with NK-1RAs and 5HT3RAs. Notes Author contributions: concept and design: Yaxiong Zhang, Yunpeng Yang, and Li Zhang; literature retrieval: Yaxiong Zhang, Yunpeng Yang, and Zhonghan Zhang; data extraction and quality assessment: Yaxiong Zhang, Zhonghan Zhang, Yunpeng Yang, and Youli Luo; statistical guidance: Yaxiong Zhang, Wenfeng Fang, Shiyang Kang, and Jin Sheng; data analysis and interpretation: Yaxiong Zhang, Yunpeng Yang, Wenfeng Fang, Jin Sheng, Jianhua Zhan, Shaodong Hong, Yan Huang, Ningning Zhou, Hongyun Zhao, and Li Zhang; manuscript writing: Yaxiong Zhang, Yunpeng Yang, Zhonghan Zhang, and Li Zhang; primary revision before submitting: all authors; final approval of manuscript: all authors. The authors have no conflicts of interest to declare. References 1. Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs. 1983;25(suppl 1): Ballatori E, Roila F. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes. 2003;1: Navari RM. Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents. Drugs. 2013;73(3): Grunberg SM, Slusher B, Rugo HS. Emerging treatments in chemotherapyinduced nausea and vomiting. Clin Adv Hematol Oncol. 2013;11(2 suppl 1):1 18; quiz 2 p following Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684(1 3): Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31): Cancer MAoSCi. MASCC/ESMO Antiemetic Guideline European Society for Medical Oncology (ESMO)/Multinational Association of Supportive Care in Cancer (MASCC), 8. Network NCC. Antiemesis: NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) (version ) National Comprehensive Cancer Network (NCCN), y1keowcqcwxxgkteg6deycjfi-y-r8kdpurqr6l0uelthbmkbhwfodbrrq2lrvo 5lYChn9E2DbabBlCB1wtOu. 9. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments metaanalysis. Lancet. 2009;373(9665): Zhang Y, Sheng J, Yang Y, et al. Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: A network metaanalysis. Oncotarget. 2016; in press. 11. Network NCC. Antiemesis: NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) (version ) National Comprehensive Cancer Network (NCCN), emesis.pdf. 12. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11): Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4): Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109): Salanti G, Higgins JP, Ades AE, et al. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17(3): Valkenhoef GV, Tervonen T, Zwinkels T, et al. ADDIS: A decision support system for evidence-based medicine. Decis Support Syst. 2012;55(2): Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97(9): de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003;21(22): Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22): Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12): Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12): Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006; 17(6): Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008;112(9): Arpornwirat W, Albert I, Hansen VL, et al. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer. 2009;115(24): Gore L, Chawla S, Petrilli A, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer. 2009;52(2): Grunberg SM, Rolski J, Strausz J, et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatinbased highly emetogenic chemotherapy: A randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(6): Herrstedt J, Apornwirat W, Shaharyar A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2009;27(32): Roila F, Rolski J, Ramlau R, et al. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol. 2009;20(11): Yeo W, Mo FK, Suen JJ, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009;113(3): Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer. 2010;18(4): Takahashi T, Hoshi E, Takagi M, et al. Multicenter, II, placebocontrolled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci. 2010;101(11): Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol EASE. J Clin Oncol. 2011;29(11):
11 11 of 11 JNCI J Natl Cancer Inst, 2017, Vol. 109, No Hesketh PJ, Wright O, Rosati G, et al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: A multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer. 2012;20(7): Saito H, Yoshizawa H, Yoshimori K, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: A multicentre, randomised, double-blind, placebo-controlled 3 trial. Ann Oncol. 2013;24(4): Tanioka M, Kitao A, Matsumoto K, et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer. 2013; 109(4): Aapro M, Rugo H, Rossi G, et al. A randomized III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25(7): Gralla RJ, Bosnjak SM, Hontsa A, et al. A III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25(7): Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapyinduced nausea and vomiting following highly emetogenic chemotherapy: A randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7): Hu Z, Cheng Y, Zhang H, et al. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: A randomized, double-blind, placebo-controlled III trial. Support Care Cancer. 2014;22(4): Ito Y, Karayama M, Inui N, et al. Aprepitant in patients with advanced nonsmall-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer. 2014;84(3): Schmitt T, Goldschmidt H, Neben K, et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: Results of a randomized, placebo-controlled III trial. J Clin Oncol. 2014;32(30): Kitayama H, Tsuji Y, Sugiyama J, et al. Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: A prospective randomized crossover study. Int J Clin Oncol. 2015;20(6): Maehara M, Ueda T, Miyahara D, et al. Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin. Anticancer Res. 2015;35(8): Nishimura J, Satoh T, Fukunaga M, et al. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled 3 trial. Eur J Cancer. 2015;51(10): Rapoport B, Chua D, Poma A, et al. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer. 2015;23(11): Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: Two randomised, active-controlled, double-blind, 3 trials. Lancet Oncol. 2015;16(9): Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: A randomised, active-controlled, double-blind, 3 trial. Lancet Oncol. 2015;16(9): Yahata H, Kobayashi H, Sonoda K, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: A multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. 2016;21(3): Ando Y, Hayashi T, Ito K, et al. Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy. Support Care Cancer. 2016;24(2): Micha JP, Rettenmaier MA, Brown JV, 3rd, et al. A randomized controlled pilot study comparing the impact of aprepitant and fosaprepitant on chemotherapy induced nausea and vomiting in patients treated for gynecologic cancer. Int J Gynecol Cancer. 2016;26(2): Weinstein C, Jordan K, Green SA, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: Results of a randomized, doubleblind III trialdagger. Ann Oncol. 2016;27(1): Wong EH, Clark R, Leung E, et al. The interaction of RS , a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995; 114(4): Grunberg SM, Koeller JM. Palonosetron: A unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother. 2003;4(12): Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a III, single-dose trial versus dolasetron. Cancer. 2003;98(11): Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10): Aapro MS, Grunberg SM, Manikhas GM, et al. A III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17(9): Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative III trial. Lancet Oncol. 2009;10(2): Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol. 2000;18(19): Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. J Clin Oncol. 1998;16(9): Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol. 2004;22(4): Fonte C, Fatigoni S, Roila F. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol Hematol. 2015;95(2): Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized III trial. J Support Oncol. 2011;9(5): Abe M, Hirashima Y, Kasamatsu Y, et al. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 II trial. Support Care Cancer. 2016;24(2):
Overview of the neurokinin-1 receptor antagonists
Editorial Page 1 of 6 Overview of the neurokinin-1 receptor antagonists Rudolph M. avari Division of Hematology Oncology, School of Medicine, University of Alabama Birmingham, Birmingham, AL, USA Correspondence
More informationMOLECULAR AND CLINICAL ONCOLOGY 2: , 2014
MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationCIC Edizioni Internazionali. Chemotherapy-induced nausea and vomiting: update and future options. Review
Review Chemotherapy-induced nausea and vomiting: update and future options Umberto Pacetti 1 Silvia Ileana Sara Fattoruso 1 Enzo Veltri 2 1 Operative Unit of Oncology, A. Fiorini Hospital, Terracina, Italy
More informationDelayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Support Care Cancer (2011) 19 (Suppl 1):S57 S62 DOI 10.1007/s00520-010-1039-y SPECIAL ARTICLE Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Fausto Roila & David
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract
1371 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(8): 1371-1377. doi: 10.7150/jca.17102 Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationPREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK
PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK HISTORY OF ANTIEMETICS 1979 A corticosteroid is superior
More informationMINI-REVIEW. Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy
MINI-REVIEW Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy Shi-Yong Wang 1 *, Zhen-Jun Yang 2, Zhe Zhang 1, Hui Zhang 1 Abstract Chemotherapy is a major
More informationChemotherapy-induced nausea and vomiting (CINV)
At a Glance Practical Implications e54 Author Information e57 Full text and PDF 5-HT3 Receptor Antagonist Effects in Cancer Patients With Multiple Risk Factors Original Research Claudio Faria, PharmD,
More informationManagement of chemotherapyinduced nausea and vomiting
p h a r m a c o t h e r a p y Management of induced nausea and vomiting Authors Key words F. Van Ryckeghem and S. Van Belle Antiemetic therapy,, prevention Summary Chemotherapy-induced nausea and vomiting
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More informationOriginal. Key words : breast cancer, chemotherapy-induced nausea and vomiting, quality of life, Functional Living Index Emesis
Showa Univ J Med Sci 30 2, 285 296, June 2018 Original The Impact on Quality of Life of Highly Effective Antiemetic Therapy among Breast Cancer Patients Receiving Anthracycline Plus Cyclophosphamide-based
More informationCancer Studies Open Access
Cancer Studies Open Access Received: Sep 16, 2014 Accepted: Oct 10, 2014 Published: Oct 14, 2014 http://dx.doi.org/10.14437/csoa-1-107 Research Hiroshi Ishiguro, Cancer Stud Open Access 2014: 1:2 Prevention
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationESMO HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE
ESMO 2016 - HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE FLORIAN SCOTTE Cancer Department Supportive Care in Cancer Unit Georges Pompidou European Hospital Paris France esmo.org DISCLOSURE SLIDE Consultant
More informationPERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER
June 2004 PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 DELAYED EMESIS WORKING
More informationAvailable online at ScienceDirect. journal homepage:
European Journal of Cancer 57 (2016) 23e30 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.ejcancer.com Original Research Efficacy and safety of rolapitant for prevention
More informationDavid G. Frame, PharmD. he etiology of nausea and vomiting is multifactorial,
r e v i e w Best Practice Management of CINV in Oncology Patients: I. Physiology and Treatment of CINV Multiple Neurotransmitters and Receptors and the Need for Combination Therapeutic Approaches David
More informationA systemic review and meta analysis of Aprepitant Combination Regimens (ACR) for prevention of Chemotherapy induced Nausea
A systemic review and meta analysis of Aprepitant Combination Regimens (ACR) for prevention of Chemotherapy induced Nausea and Vomiting (CINV) in adults Fahad Zubair, PGY 3 UB CHS Internal Medicine Nausea
More informationClinical Review Report
CADTH COMMON DRUG REVIEW Clinical Review Report Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma) Indication: In combination with dexamethasone, onceper-cycle treatment for the prevention
More informationReviews on Recent Clinical Trials
Reviews on Recent Clinical Trials Send Orders for Reprints to reprints@benthamscience.ae 193 Reviews on Recent Clinical Trials, 2017, 12, 193-201 REVIEW ARTICLE ISSN: 1574-8871 eissn: 1876-1038 : An NK-1
More informationClass Update with New Drug Evaluation: Antiemetics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology October 2015 Advances in the Management of Chemotherapy-Induced ausea and Vomiting: ew Data From Recent and Ongoing Trials Discussants
More informationThalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
Thalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Geng Song, Qian He, Fanfan Li, and Nianfei Wang Department of Oncology, The Second Affiliated
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationReview Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced
More informationANTIEMETIC RESEARCH AND PROGRESS: Richard J. Gralla, MD, FACP Professor of Medicine Albert Einstein College of Medicine Bronx, New York
ANTIEMETIC RESEARCH AND PROGRESS: Richard J. Gralla, MD, FACP Professor of Medicine Albert Einstein College of Medicine Bronx, New York THE FUTURE OF ANTIEMETICS Fausto Roila Medical Oncology, Terni, Italy
More informationIntroduction ORIGINAL ARTICLE. Paul J. Hesketh 1 & Marco Palmas 2 & Pierre Nicolas 3
Support Care Cancer (18) 26:1151 1159 https://doi.org/.7/s5-17-3936-9 ORIGINAL ARTICLE Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of (netupitant-palonosetron),
More informationDrug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.
Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc. Pharmacology: Aprepitant (previously known as MK-0839 and L-754030) is a new molecular entity that is the first in a new therapeutic class,
More informationOpen Access RESEARCH. Miya et al. SpringerPlus (2016) 5:2080 DOI /s x. *Correspondence: 1
DOI 10.1186/s40064-016-3769-x RESEARCH Open Access Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy induced nausea and vomiting in patients receiving carboplatin
More informationHHS Public Access Author manuscript N Engl J Med. Author manuscript; available in PMC 2017 March 09.
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting Rudolph M. Navari, M.D., Rui Qin, Ph.D., Kathryn J. Ruddy, M.D., Heshan Liu, Ph.D., Steven F. Powell, M.D., Madhuri Bajaj, M.D.,
More informationInternational Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany. What was hot at MASCC/ISOO Annual Meeting this year?
International Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany What was hot at MASCC/ISOO Annual Meeting this year? Supportive Care Makes Excellent Cancer Care Possible. This slogan
More informationRichard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY
Oncology Consultations Improving the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) A CE-Certified Activity Featuring Consultations With Supported by an educational grant from Eisai. Dannemiller
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationNeurokinin-1 Receptor Antagonists for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review
DOI:10.1093/jnci/djs335 Advance Access publication on August 21, 2012. The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationORIGINAL ARTICLE. Ralph Boccia & Steven Grunberg & Edwin Franco-Gonzales & Edward Rubenstein & Daniel Voisin
Support Care Cancer (2013) 21:1453 1460 DOI 10.1007/s00520-012-1691-5 ORIGINAL ARTICLE Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology March 2015 New and Emerging Therapeutic Options for the Management of Chemotherapy-Induced Nausea and Vomiting Discussants Lee S.
More informationUpdate on antiemetics, what is new and future directions. Karin Jordan University of Halle
Update on antiemetics, what is new and future directions Karin Jordan University of Halle History of Antiemetics Controlling Chemotherapy-Induced EMESIS: Progress Over The Past 30 Years: Efficacy 5-Day
More informationPediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives
Nausea and Vomiting Control in Adults and Children: Mind the Gap! Disclosures No relevant conflicts of interest Lee Dupuis, RPh, PhD May 5, 2018 2 Learning Objectives At the end of this presentation, attendees
More informationAcute emesis: moderately emetogenic chemotherapy
Support Care Cancer (2005) 13:97 103 DOI 10.1007/s00520-004-0701-7 R E V I E W R T I C L E Jørn Herrstedt Jim M. Koeller Fausto Roila Paul J. Hesketh David Warr Cynthia Rittenberg Mario Dicato cute emesis:
More informationOlanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
The new england journal of medicine Original Article for the Prevention of Chemotherapy-Induced Nausea and Vomiting Rudolph M. Navari, M.D., Rui Qin, Ph.D., Kathryn J. Ruddy, M.D., Heshan Liu, Ph.D., Steven
More information9/21/2016. Disclosures. Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Introduction. Objectives.
Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Diwura Owolabi, Pharm.D, BCOP Clinical Pharmacy Specialist, Blood and Marrow Transplantation Methodist University Hospital,
More informationExpression of programmed death ligand-1 on tumor cells varies pre and post
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer Jin Sheng 1,2,3,*, Wenfeng Fang 1,2,3,*, Juan Yu 3, Yunpeng Yang 1,2,3, Yuxiang Ma
More informationAdherence to guidelines on prophylaxis of chemotherapy-induced nausea and vomiting in the National Cancer Institute, Sudan
Southern African Journal of Gynaecological Oncology 2017; 9(2):7-11 Open Access article distributed under the terms of the Creative Commons License [CC BY-NC-ND 4.0] http://creativecommons.org/licenses/by-nc-nd/4.0
More informationCME. The faculty reported the following financial relationships or relationships to
CME Target Audience This activity has been designed to meet the educational needs of oncologists, hematologists, and oncology nurses involved in the management of cancer patients receiving chemotherapy.
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationCHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to the edit Experts Master
More informationAn Evidence Practice Gap in Antiemetic Prescription with Chemotherapy
2014 An Evidence Practice Gap in Antiemetic Prescription with Chemotherapy Chepsy C Philip 1*, Biju George 1 1 Department of Clinical Haematology, CMC Vellore, Tamil Nadu, India. ARTICLE INFO Article type:
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationCDR May Aprepitant Emend Merck Frosst Canada Ltd. Indication Chemotherapy-induced Nausea and Vomiting
Overview of CDR Clinical and Pharmacoeconomic Reports CDR May 2008 Aprepitant Emend Merck Frosst Canada Ltd. Indication Chemotherapy-induced Nausea and Vomiting Cite as: Common Drug Review. Aprepitant
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationComparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
569 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(5): 569-575. doi: 10.7150/jca.13637 Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk
More information, Gianluca Ballinari. ) receptor antagonist,
Leukemia & Lymphoma, March 2014; 55(3): 544 550 2014 Informa UK, Ltd. ISSN: 1042-8194 print / 1029-2403 online DOI: 10.3109/10428194.2013.813498 ORIGINAL ARTICLE: CLINICAL Multicenter phase IV study of
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPing-Tsung Chen, MD; Chuang-Chi Liaw, MD
Original Article 167 Intravenous Ondansetron plus Intravenous Dexamethasone with Different Ondansetron Dosing Schedules during Multiple Cycles of Cisplatin-based Chemotherapy Ping-Tsung Chen, MD; Chuang-Chi
More informationSafety, efficacy, and patient acceptability of singledose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
Patient Preference and Adherence open access to scientific and medical research Open Access Full Text Article Review Safety, efficacy, and patient acceptability of singledose fosaprepitant regimen for
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationANTICANCER RESEARCH 33: (2013)
Improvement of Adherence to Guidelines for Antiemetic Medication Enhances Emetic Control in Patients with Colorectal Cancer Receiving Chemotherapy of Moderate Emetic Risk HIRONORI FUJII 1, HIROTOSHI IIHARA
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationChemotherapy-Related Nausea and Vomiting and Treatment-Related Nausea and Vomiting
CHAPTER 12 Chemotherapy-Related Nausea and Vomiting and Treatment-Related Nausea and Vomiting Elizabeth Blanchard T he ability of chemotherapy to cause nausea and vomiting is legendary and remains a widespread
More informationDrug Class Literature Scan: Newer Antiemetics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationRecent Advances and Updated Guidelines in the Management of Chemotherapy-Induced Nausea and Vomiting
N o v e m b e r 2 0 1 1 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 9, I s s u e 1 1, S u p p l e m e n t 2 7 Moderator Discussants Lee S. Schwartzberg, MD, FACP Clinical Oncologist Medical
More informationDrug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy
REVIEW Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy R. Schoffelen 1 *, A.G. Lankheet 2, C.M.L. van Herpen 1, J.J.M. van der Hoeven 1, I.M.E. Desar 1, C. Kramers 3 Departments
More informationUsing a Simple Diary for Management of Nausea and Vomiting During Chemotherapy
Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy Problem identification Nausea and vomiting (N&V) are frequent complications following chemotherapy, even when taking 5-HT3
More informationEfficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens
Yoshida et al. BMC Pharmacology and Toxicology (2019) 20:6 https://doi.org/10.1186/s40360-018-0278-2 RESEARCH ARTICLE Efficacy of the combination use of aprepitant and palonosetron for improving nausea
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationRolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting Tamara Goldberg, PharmD, BCPS; Brooke Fidler, PharmD; and Stephanie Cardinale,
More informationConflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives
Conflicts of Interest No financial relationships to disclose Review of Antiemetic Guidelines Matthew Fox, PharmD, BCPS, BCOP Clinical Oncology Pharmacist Baptist MD Anderson Jacksonville, Florida October
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSerum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting
https://doi.org/1.7/s1147-18-1321-4 ORIGINAL ARTICLE Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting Toshimichi Miya 1,2 Haruhiko Kondo 1 Akihiko
More information2. Name of the organization(s) consulted and/or supporting the application European Society for Medical Oncology (ESMO)
Title: Proposal for the inclusion of Aprepitant as antiemetic drug for the supportive care of cancer patients receiving moderately to highly cytotoxic chemotherapy in the Essential List of Medicines of
More informationCan Granisetron Injection Used as Primary Prophylaxis Improve the Control of Nausea and Vomiting with Low- Emetogenic Chemotherapy?
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.1.469 RESEARCH ARTICLE Can Granisetron Injection Used as Primary Prophylaxis Improve the Control of Nausea and Vomiting with Low- Emetogenic Chemotherapy? Chan
More informationInsights. Antiemesis, Version Featured Updates to the NCCN Guidelines. NCCN Guidelines Insights
NCCN Guidelines Insights Antiemesis 883 NCCN Guidelines Insights Featured Updates to the NCCN Guidelines Michael J. Berger, PharmD, BCOP 1,* ; David S. Ettinger, MD 2,* ; Jonathan Aston, PharmD, BCOP,
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDrug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting
Texas Vendor Drug Program Drug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting Publication History Developed September 1996. Revised July 2018; September 2016; June 2015;
More informationClinical Policy: Oral Antiemetics (5-HT3 Antagonists) Reference Number: CP.PMN.11 Effective Date: Last Review Date: 05.18
Clinical Policy: (5-HT3 Antagonists) Reference Number: CP.PMN.11 Effective Date: 09.01.06 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy
More informationPublished Ahead of Print on September 26, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on September 26, 2011 as 10.1200/JCO.2010.34.4614 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.34.4614 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C
More informationChemotherapy-induced nausea and vomiting
O R I G I N A L R E S E A R C H Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial Rudolph M. Navari, MD, PhD, Sarah E. Gray, BS,
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationChemotherapy-induced nausea and vomiting
Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children Veerendra Patil, MD, FNB; Harsha Prasada, MD, DCH,
More informationManaging chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation
Original Article Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation Jordan Stinson, Kelvin Chan, Justin Lee, Ronald
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationCADTH COMMON DRUG REVIEW Pharmacoeconomic Review Report
CADTH COMMON DRUG REVIEW Pharmacoeconomic Review Report Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma) Indication: In combination with dexamethasone, once-percycle treatment for the prevention
More informationEffects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery
Clinical Report Effects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery Journal of International Medical Research 2018, Vol. 46(1) 411 420! The Author(s) 2017
More informationPrevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
Annals of Oncology 17: 20 28, 2006 doi:10.1093/annonc/mdj078 Published online 28 November 2005 Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationNausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea
Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,
More informationNeurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting
Review Article Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting Fahad Aziz Department of Internal Medicine, Section on Hospital Medicine, Wake Forest University Medical Center,
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationStudent Project PRACTICE-BASED RESEARCH
Pharmacist-Driven Management of Chemotherapy Induced Nausea and Vomiting in Hospitalized Adult Oncology Patients. A Retrospective Comparative Study Ramy Elshaboury, PharmD 1 and Kathleen Green, PharmD,
More informationOrganizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD
PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 Organizing and Overall Meeting
More informationANTIEMETICS and FEBRILE NEUTROPENIA. Matti S. Aapro Genolier Switzerland
ANTIEMETICS and FEBRILE NEUTROPENIA Matti S. Aapro Genolier Switzerland 2010 Multinational Association of Supportive Care in Cancer TM All rights reserved worldwide. Disclosures Collaborations in this
More informationChemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control
Chemotherapy-Induced Nausea and Vomiting Strategies for Achieving Learning Objectives Describe the challenges of assessing nausea in patients undergoing chemotherapy and the impact of nausea and also vomiting
More informationComparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting
Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting Sayantani Ghosh, Saugat Dey Corresponding author: Sayantani Ghosh (ghoshsayantani@rediffmail.com) Correspondence concerning
More informationReview Article Moxibustion for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis
Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2017, Article ID 9854893, 11 pages https://doi.org/10.1155/2017/9854893 Review Article Moxibustion for Chemotherapy-Induced Nausea and
More information